Research programme: peptides therapeutics - Interprotein/Ipsen

Drug Profile

Research programme: peptides therapeutics - Interprotein/Ipsen

Latest Information Update: 20 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Interprotein Corporation; Ipsen
  • Class Peptides; Proteins
  • Mechanism of Action Immunomodulators; Peptide modulators; Protein-protein interaction inhibitors; Protein-protein interaction modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Endocrine disorders

Most Recent Events

  • 30 Dec 2015 Ipsen and Interprotein agree to co-promote and co-develop peptide therapeutics in US for endocrine disorders
  • 19 Nov 2015 Preclinical development for Endocrine disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top